sUA Lowering Therapies:The why, the when, the how!

Presenter:

Speaker Disclosure Statement

Name of presenter/speaker sUA Lowering Therapies:

The why, the when, the how!Financial Disclosure: – Grants/Research Support – Speaker Bureau/Honoraria – Consulting Fees – Other

Mean Serum Urate, µmol/L

Per

cent

age

of P

atie

nts

With

G

out F

lare

Rec

urre

nce

0

20

40

60

80

100

Reduction in Acute Flaresin Years 2 and 3 of Treatment1

N = 267

.

.

0

10

20

30

40

50

0-4 4-8 8-12 12-16 16-20 20-24 24-28

Time interval (weeks)

Subj

ects

, %

Febuxostat 80 mg Allopurinol 300/200 mg